Responding to the immunoglobulin shortage: A case study

Journal of Health Politics, Policy and Law

Volumn 27, Issue 6, 2002, Pages 977-999

  Boulis, Ann ^a   Goold, Susan ^a   Ubel, Peter A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; VACCINE;

ARTICLE; COOPERATION; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; GOVERNMENT; HEALTH CARE AVAILABILITY; HEALTH CARE DISTRIBUTION; HEALTH CARE INDUSTRY; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; MARKET; UNITED STATES;

EID: 0036972268     PISSN: 03616878     EISSN: None     Source Type: Journal    
DOI: 10.1215/03616878-27-6-977     Document Type: Article

References (27)

1. Advisory Committee on Blood Safety and Availability (BSAC). 1997. Summary of meeting held 11-12 August. Available on-line at www.hhs.gov/bloodsafety/ summaries/sumaug97.html.
2. _, 1998. Transcript of meeting held 27-28 August. Available on-line at www.hhs.gov/bloodsafety/transcripts/19980928.html.
3. American Blood Resources Association (ABRA) (now the Plasma Protein Therapeutics Association [PPTA]). 2000. Plasma and Plasma Products Industry Economics and Demographics. On-line material from the ABRA Web site (no longer available).
4. American Medical Association (AMA). Council on Ethical and Judicial Affairs. 1995. Ethical Considerations in the Allocation of Organs and Other Scarce Medical Resources among Patients. Archives of Internal Medicine 155:29-40.
5. Amsden, R. 1998. Nationwide Blood Plasma Woes Hit Home in Alton. Manchester (NH) Union Leader, 10 February, A8.
6. Availability of Immune Globulin Intravenous for Treatment of Immune Deficient Patients - United States, 1997-1998. 1999. Morbidity and Mortality Weekly Report 48(08):159-162.
7. Bult, J. 1998. Safety of Blood Plasma Products. Testimony before U.S. House, Committee on Government Reform and Oversight, Subcommittee on Human Resources. 105th Cong., 2d sess., 9 September.
8. Caplan, Arthur. 1999. Transcript of meeting of the Advisory Committee on Blood Safety and Availability (BSAC) held 26 August. Available on-line at www.hhs.gov/bloodsafety/transcripts/aug26_99.html.
9. Chen, C., L. H. Danekas, T. A. Ratko, P. H. Vlasses, and K. A. Matuszewski. 2000. A Multicenter Drug Use Surveillance of Intravenous Immunoglobin Utilization in U.S. Academic Health Centers. Annals of Pharmacotherapy 34:295-259.
10. Dalakas, M. C. 1997. Intravenous Immune Globulin Therapy for Neurologic Diseases. Annals of Internal Medicine 126:721-730.
11. Eichenwald, K. 1998. Strangled Lifeline: A Special Report; Shortage of Plasma Drug Creates Health Care Crisis. New York Times, 26 April, A1.
12. Fleck, L. 1990. Justice, HMOs, and the Invisible Rationing of Health Care Resources. Bioethics 4:97-120.
13. Imbach, P., S. Barandun, C. Baumgartner, A. Hirt, F. Hofer, and H. P. Wagner. 1981. High-dose Intravenous Gammaglobulin Therapy of Refractory, in Particular, Idiopathic Thrombocytopenia in Childhood. Helvetica Paediatrica Acta 36(1):81-86.
14. Jackman, D. 1999. Perspective on Supply and Demand of Plasma Products. Testimony at 16 June meeting of Blood Products Advisory Committee. Available on-line at www.fda.gov/ohrms/dockets/ac/cber99.htm#.
15. LaMendola, B. 1998. Globulin Shortage a Life or Death Matter; Product Made from Donated Blood Helps Weak Immune Systems. Fort Lauderdale Sun-Sentinel, 12 January, 1B.
16. Leveton, L., H. Sox, and M. Soto. 1996. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Transfusion 36:919-927.
17. Lore, D. 1997. Hospitals Conserve Supplies of Antibody Booster. Columbus (OH) Dispatch, 21 December, 1E.
18. National Institutes of Health (NIH). 1990. Intravenous Immunoglobulin: Prevention and Treatment of Disease. NIH Consens Statement Online 8(5):1-23.
19. Powers, M. 1997. Blood-Product Shortage Hurts St. Jude. Memphis (TN) Commercial Appeal, 20 December, A13.
20. Ratko, T. A., D. A. Burnett, G. E. Foulke, K. Matuszewski, and R. Sacher. 1995. Recommendations for Off-Label Use of Intravenously Administered Immunoglobulin Preparations. Journal of the American Medical Association 273:1865-1870.
21. Schmidt, P. 1999. Testimony before the Food and Drug Administration, Blood Products Advisory Committee, Washington, DC, 17 June.
22. _, 2001. Testimony before meeting of the Advisory Committee on Blood Safety and Availability, Washington, DC, 20 April.
23. Starr D. 1998. Blood: An Epic History of Medicine and Commerce. New York: Alfred A. Knopf.
24. Tarlach, G. M. 1998. Globulin Goblins: Shortfall in Immune Globulin Supplies Looms. Drug Topics 142:16.
25. Ubel, P. A., and A. L. Caplan. 1998. Geographic Favoritism in Liver Transplantation: Unfortunate or Unfair? New England Journal of Medicine 339:1322-1325.
26. Ubel, P. A., M. L. DeKay, J. Baron, and D. A. Asch. 1996. Cost-Effectiveness Analysis in a Setting of Budget Constraints: Is It Equitable? New England Journal of Medicine 334:1174-1177.
27. Zoon, K. C. 1997. Testimony before U.S. House, Committee on Government Reform and Oversight, Subcommittee on Human Resources and Intergovernmental Relations. 105th Cong., 1st sess., 31 July.